Two	O
novel	O
and	O
functional	O
DNA	O
sequence	O
variants	O
within	O
an	O
upstream	O
enhancer	O
of	O
the	O
human	O
NKX2	O
-	O
5	O
gene	O
in	O
ventricular	B-DISEASE
septal	I-DISEASE
defects	E-DISEASE
.	O


Mortality	O
in	O
patients	O
with	O
congenital	B-DISEASE
heart	I-DISEASE
disease	E-DISEASE
(	O
CHD	S-DISEASE
)	O
is	O
significantly	O
increased	O
even	O
with	O
successful	O
surgeries	O
.	O


The	O
main	O
causes	O
are	O
late	O
cardiac	O
complications	O
,	O
such	O
as	O
heart	B-DISEASE
failure	E-DISEASE
and	O
arrhythmia	O
,	O
probably	O
due	O
to	O
genetic	B-DISEASE
defects	E-DISEASE
.	O


To	O
date	O
,	O
genetic	O
causes	O
for	O
CHD	S-DISEASE
remain	O
largely	O
unknown	O
.	O


NKX2	O
-	O
5	O
gene	O
encodes	O
a	O
highly	O
conserved	O
homeobox	O
transcription	O
factor	O
,	O
which	O
is	O
essential	O
to	O
the	O
heart	O
development	O
in	O
embryos	O
and	O
cardiac	O
function	O
in	O
adults	O
.	O


Mutations	O
in	O
NKX2	O
-	O
5	O
gene	O
have	O
been	O
implicated	O
in	O
diverse	O
types	O
of	O
CHD	S-DISEASE
,	O
including	O
ventricular	B-DISEASE
septal	I-DISEASE
defect	E-DISEASE
(	O
VSD	S-DISEASE
)	O
.	O


As	O
NKX2	O
-	O
5	O
is	O
a	O
dosage	O
-	O
sensitive	O
regulator	O
,	O
we	O
have	O
speculated	O
that	O
changed	O
NKX2	O
-	O
5	O
levels	O
may	O
mediate	O
CHD	S-DISEASE
development	O
by	O
influencing	O
cardiac	O
gene	O
regulatory	O
network	O
.	O


In	O
previous	O
studies	O
,	O
we	O
have	O
analyzed	O
the	O
NKX2	O
-	O
5	O
gene	O
promoter	O
and	O
a	O
proximal	O
enhancer	O
in	O
VSD	S-DISEASE
patients	O
.	O


In	O
the	O
present	O
study	O
,	O
we	O
further	O
genetically	O
and	O
functionally	O
analyzed	O
an	O
upstream	O
enhancer	O
of	O
the	O
NKX2	O
-	O
5	O
gene	O
in	O
large	O
cohorts	O
of	O
VSD	S-DISEASE
patients	O
(	O
n	O
=	O
340	O
)	O
and	O
controls	O
(	O
n	O
=	O
347	O
)	O
.	O


Two	O
novel	O
heterozygous	O
DNA	O
sequence	O
variants	O
(	O
DSVs	O
)	O
,	O
g	O
.	O
17483576C	O
>	O
G	O
and	O
g	O
.	O
17483564C	O
>	O
T	O
,	O
were	O
identified	O
in	O
three	O
VSD	S-DISEASE
patients	O
,	O
but	O
none	O
in	O
controls	O
.	O


Functionally	O
,	O
these	O
two	O
DSVs	O
significantly	O
decreased	O
the	O
activity	O
of	O
the	O
enhancer	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O


Another	O
novel	O
heterozygous	O
DSV	O
,	O
g	O
.	O
17483557Ins	O
,	O
was	O
found	O
in	O
both	O
VSD	S-DISEASE
patients	O
and	O
controls	O
with	O
similar	O
frequencies	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O


Taken	O
together	O
,	O
our	O
data	O
suggested	O
that	O
the	O
DSVs	O
within	O
the	O
upstream	O
enhancer	O
of	O
the	O
NKX2	O
-	O
5	O
gene	O
may	O
contribute	O
to	O
a	O
small	O
number	O
of	O
VSD	S-DISEASE
.	O


Therefore	O
,	O
genetic	O
studies	O
of	O
CHD	S-DISEASE
may	O
provide	O
insight	O
into	O
designing	O
novel	O
therapies	O
for	O
adult	O
CHD	S-DISEASE
patients	O
.	O
